Table 2.

Summary of novel immunotherapeutic strategies for melanoma patients.

Target	Therapeutic strategy	Reference
Topoisomerase I	Topoisomerase I inhibitor + anti-PD-L1 or anti-PD1 mAbs	[79]
Polypeptide gp75	Anti gp75 mAb + anti-PD1 mAb	[81]
Histone deacetylase (HDAC)	Pan-HDAC inhibitors + anti-PD1 mAb	[82]
Fas	Fas/Fas-ligand blocking mAbs	[83]
CD40	Anti-CD40 mAb + CpG ODNs	[84]
CTLA-4 and GD2	Anti-CTL-A4 mAb + anti-GD2 mAb conjugated with IL-2	[84]
Regulatory cells	Foxp3 DNA/recombinant protein vaccine	[85]
GP33-41 antigen	Adenoviral vector expressing GP33-41 tumor-associated antigen	[86]
Unknown	Docetaxel + adoptive T cell transfer + DC immunotherapy	[93]
MART-1	MART-1-specific CD8+ T cells	[94]